Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

December 01, 2015 5:32 PM ET


Company Overview of ImmusanT, Inc.

Company Overview

ImmusanT, Inc., a biotechnology company, develops treatment and diagnostic and monitoring tools to manage patients with celiac disease. The company offers Nexvax2, a peptide-based therapeutic vaccine that is designed to re-establish patients’ tolerance to the toxic effects of gluten, a protein in wheat, barley, and rye and allow them to return to a normal diet. ImmusanT, Inc. was founded in 2010 and is based in Cambridge, Massachusetts with clinical trials in New Zealand, Australia, and the United States.

One Kendall Square

Suite B2004

Cambridge, MA 02139

United States

Founded in 2010





Key Executives for ImmusanT, Inc.

Founder, Chief Executive Officer, President and Director
Chief Financial Officer and Secretary pro tem
Director of Finance and Operations
Chief Medical Officer
Compensation as of Fiscal Year 2015.

ImmusanT, Inc. Key Developments

ImmusanT, Inc. Announces Executive Appointments

ImmusanT, Inc. announced the appointment of Michael Cooreman, M.D., Ph.D., as Chief Medical Officer and Anita Treohan as Director of Clinical Operations. Dr. Cooreman brings to ImmusanT extensive experience in clinical development and translational medicine. As Chief Medical Officer, he will lead all clinical development programs, including the development of Nexvax2®, ImmusanT’s lead product candidate for the treatment of celiac disease. Ms. Treohan joins the company with diverse global clinical development and strategic experience across multiple therapeutic areas. As Director of Clinical Operations, Ms. Treohan will be responsible for the management of ImmusanT’s clinical programs, including the upcoming Phase 2 trials of Nexvax. Dr. Cooreman joins ImmusanT from Mitsubishi Tanabe, where he served as Executive Director for Clinical Research and Head of Metabolism, Infectious Diseases and Oncology. Most recently, Ms. Treohan served as Director of Clinical Operations at FORUM Pharmaceuticals Inc.

ImmusanT, Inc. Presents at Boston CEO Conference, May-26-2015 04:30 PM

ImmusanT, Inc. Presents at Boston CEO Conference, May-26-2015 04:30 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Speakers: Leslie J. Williams, Founder, Chief Executive Officer, President and Director.

ImmusanT, Inc. Presents at 13th Annual BIO Investor Forum, Oct-07-2014

ImmusanT, Inc. Presents at 13th Annual BIO Investor Forum, Oct-07-2014 . Venue: The Palace Hotel, San Francisco, CA 94105, United States.

Similar Private Companies By Industry

Company Name Region
Beardsworth Consulting Group, Inc. United States
Yasoo Health Inc. United States
FemmePharma Global Healthcare, Inc. United States
X4 Pharmaceuticals Inc. United States
Aponia Laboratories Inc. United States

Recent Private Companies Transactions

Private Placement
December 19, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ImmusanT, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at